These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C. Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848 [No Abstract] [Full Text] [Related]
9. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure. Cohen J Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268 [No Abstract] [Full Text] [Related]
10. First-in-class insomnia drug on the brink of approval nod. Osborne R Nat Rev Drug Discov; 2013 Jul; 12(7):492-3. PubMed ID: 23812257 [No Abstract] [Full Text] [Related]
11. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. Med Lett Drugs Ther; 2013 Sep; 55(1424):75-6. PubMed ID: 24043217 [No Abstract] [Full Text] [Related]
12. New drug update: 2007. Hussar DA Consult Pharm; 2008 Apr; 23(4):276-96. PubMed ID: 18454587 [TBL] [Abstract][Full Text] [Related]
13. Drug updates and approvals: 2014 in review. Sigler J Nurse Pract; 2014 Dec; 39(12):14-23; quiz 23-4. PubMed ID: 25350291 [TBL] [Abstract][Full Text] [Related]
14. Drug updates and approvals: 2017 in review. Mospan G; Mospan C; Vance S; Bradshaw A; Meosky K; Bowles K Nurse Pract; 2017 Dec; 42(12):8-16. PubMed ID: 29176433 [TBL] [Abstract][Full Text] [Related]
15. New antiplatelet agent approved. Traynor K Am J Health Syst Pharm; 2014 Jun; 71(12):977. PubMed ID: 24865749 [No Abstract] [Full Text] [Related]
16. FDA cancels approval for bevacizumab in advanced breast cancer. Tanne JH BMJ; 2011 Nov; 343():d7684. PubMed ID: 22121166 [No Abstract] [Full Text] [Related]
17. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia. Small S Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628 [No Abstract] [Full Text] [Related]
18. New drugs 2020, part 3. Hussar DA Nursing; 2020 Oct; 50(10):32-41. PubMed ID: 32947372 [TBL] [Abstract][Full Text] [Related]
19. Canagliflozin: a new drug for type 2. Goldman-Levine J Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597 [No Abstract] [Full Text] [Related]
20. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Akha AS; Rosa J; Jahr JS; Li A; Kiai K Anesthesiol Clin; 2010 Dec; 28(4):691-708. PubMed ID: 21074746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]